Ask AI
ProCE Banner Activity

Best Practices for Integration of Biomarker and Genetic Mutation Testing in Clinical Practice

Slideset

Downloadable slides from a live symposium covering best practices for biomarker and genetic testing in metastatic prostate cancer.

Released: February 25, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate genetic testing workflows in concordance with guideline recommendations for all HRR mutations to identify patients who may benefit from PARP inhibitor-based therapy

  • Integrate strategies to identify and address barriers to appropriate genetic and biomarker testing for patients with mPC, including testing workflows and the role of the multidisciplinary care team